Health Canada Has Received A Submission From Novavax For Their Covid-19 Vaccine Targeting Omicron XBB.1.5 Subvariant For People 12 Years And Older
Portfolio Pulse from Benzinga Newsdesk
Novavax has submitted their Covid-19 vaccine targeting the Omicron XBB.1.5 subvariant for people aged 12 and older to Health Canada for approval.
September 12, 2023 | 3:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novavax's submission of their Covid-19 vaccine to Health Canada could potentially boost the company's stock if the vaccine is approved.
The news of Novavax's submission to Health Canada is directly related to the company and its stock. If the vaccine is approved, it could lead to increased sales and revenue for Novavax, which would likely have a positive impact on the company's stock price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100